@techreport{oai:kanazawa-u.repo.nii.ac.jp:00050456,
 month = {May},
 note = {本研究では、加速器を用いた核反応で製造した^<230>Paを利用して、^<230>U/^<226>Thジェネレータの製造法を検討した。また、ミルキングした^<226>Thで標識した^<226>Th-EDTMPの骨集積に関する検討を行った。その結果、比較的簡単な化学分離で^<230>U/^<226>Thジェネレータを製造することに成功し、さらにミルキングした^<226>Thの標識化合物^<226>Th-EDTMPをマウスに尾静脈投与し、^<226>Th-EDTMPの骨への集積を確認した。, Targeted alpha therapy (TAT) has been applied for cancer therapy and many clinical studies have been performed. Uranium-230 is a promising cyclotron produced alpha-emitting radionuclide for TAT. According to the reaction ^<232>Th(p, 3n)^<230>Pa and following the β- decay of ^<230>Pa, ^<230>U can be produced within the irradiated target. The daughter of ^<230>U, ^<226>Th (T_<1/2>=31m) provides a rapid cascade of 4 alpha particles with a 27.7MeV of total energy. In this study, we investigated the availability of production and radiochemical separation of ^<230>U and its daughters. Protactinium-230 was produced by irradiation of ^<232>ThO_2 target. After irradiation, the target was separated and ^<230>U/^<226>Th generator was constructed. Eluted ^<226>Th from generator was radiolabeled with bone seeking chelate, EDTMP and injected into mice for biodistribution evaluation. Most of all radioactivity were retained on bone., 出典：研究課題「加速器生産α線放出核種の内用放射療法への適応」課題番号20790886
（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） 
（https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-20790886/20790886seika/）を加工して作成, 金沢大学医薬保健研究域保健学系},
 title = {加速器生産α線放出核種の内用放射療法への適応},
 year = {2011}
}